(Q35758705)

10 August 2017

1 reference

title

Chlamydia pneumoniae and atherosclerosis: no way-out or long way? What about renal failure patients? (English)

1 reference

10 August 2017

Chlamydia pneumoniae

1 reference

George Tsirpanlis

1

1 reference

10 August 2017

publication date

26 April 2004

1 reference

Kidney and Blood Pressure Research

10 August 2017

published in

1 reference

10 August 2017

volume

27

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

134-142

1 reference

The role of Chlamydia in coronary heart disease-fact or fiction?

10 August 2017

cites work

1 reference

Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease

21 January 2018

1 reference

Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies

21 January 2018

1 reference

Chlamydia pneumoniae and atherosclerosis -- what we know and what we don't

21 January 2018

1 reference

Interactions of Chlamydia pneumoniae with human endothelial cells

21 January 2018

1 reference

Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages

21 January 2018

1 reference

21 January 2018

1 reference

cDNA array analysis of altered gene expression in human endothelial cells in response to Chlamydia pneumoniae infection

21 January 2018

1 reference

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

Growth in vascular cells and cytokine production by Chlamydia pneumoniae

21 January 2018

1 reference

Polymorphic membrane protein (PMP) 20 and PMP 21 of Chlamydia pneumoniae induce proinflammatory mediators in human endothelial cells in vitro by activation of the nuclear factor-kappaB pathway.

21 January 2018

1 reference

Chlamydia pneumoniae activates epithelial cell proliferation via NF-kappaB and the glucocorticoid receptor

21 January 2018

1 reference

Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression

21 January 2018

1 reference

Increased production of matrix metalloproteinases 1 and 3 by smooth muscle cells upon infection with Chlamydia pneumoniae

21 January 2018

1 reference

Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis

21 January 2018

1 reference

Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway

21 January 2018

1 reference

Egr-1, a major link between infection and atherosclerosis?

21 January 2018

1 reference

Chlamydia pneumoniae inhibits apoptosis in human peripheral blood mononuclear cells through induction of IL-10.

21 January 2018

1 reference

Chlamydia pneumoniae inhibits apoptosis in human epithelial and monocyte cell lines

21 January 2018

1 reference

Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for [correction of factors is required for] major histocompatibility complex antigen expression

21 January 2018

1 reference

Chlamydia pneumoniae pathogenesis

21 January 2018

1 reference

Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice

21 January 2018

1 reference

Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice

21 January 2018

1 reference

Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice

21 January 2018

1 reference

Chlamydia pneumoniae and hyperlipidemia are co-risk factors for atherosclerosis: infection prior to induction of hyperlipidemia does not accelerate development of atherosclerotic lesions in C57BL/6J mice

21 January 2018

1 reference

Chronic infections and coronary heart disease: is there a link?

21 January 2018

1 reference

Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis

21 January 2018

1 reference

Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis

21 January 2018

1 reference

Meta-analysis of sero-epidemiologic studies of the relation between Chlamydia pneumoniae and atherosclerosis: does study design influence results?

21 January 2018

1 reference

Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens

21 January 2018

1 reference

Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease

21 January 2018

1 reference

Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease

21 January 2018

1 reference

Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate.

21 January 2018

1 reference

Chlamydia pneumoniae in the atherosclerotic plaques of patients with unstable angina undergoing coronary artery bypass grafting: does it have prognostic implications?

21 January 2018

1 reference

Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of humans and koalas

21 January 2018

1 reference

Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae

21 January 2018

1 reference

Chronic infection and coronary artery disease

21 January 2018

1 reference

Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada).

21 January 2018

1 reference

Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols

21 January 2018

1 reference

Comparison of an industry-derived LCx Chlamydia pneumoniae PCR research kit to in-house assays performed in five laboratories

21 January 2018

1 reference

Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction

21 January 2018

1 reference

Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study

21 January 2018

1 reference

Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA).

21 January 2018

1 reference

Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome

21 January 2018

1 reference

Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial

21 January 2018

1 reference

Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial

21 January 2018

1 reference

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial

21 January 2018

1 reference

Description and status of the azithromycin and coronary events study (ACES).

21 January 2018

1 reference

Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial

21 January 2018

1 reference

Antibiotic treatment of atherosclerotic cardiovascular disease

21 January 2018

1 reference

Chlamydia pneumoniae resists antibiotics in lymphocytes

21 January 2018

1 reference

Anti-inflammatory effects of macrolide antibiotics

21 January 2018

1 reference

Inflammation is associated with carotid atherosclerosis in dialysis patients. Creed Investigators. Cardiovascular Risk Extended Evaluation in Dialysis Patients.

21 January 2018

1 reference

C-reactive protein and chronic Chlamydia pneumoniae infection--long-term predictors for cardiovascular disease and survival in patients on peritoneal dialysis

21 January 2018

1 reference

Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients

21 January 2018

1 reference

Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure

21 January 2018

1 reference

Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in dialysis patients, renal transplant recipients and healthy controls

21 January 2018

1 reference

Detection of Chlamydia pneumoniae in peripheral blood mononuclear cells: correlation with inflammation and atherosclerosis in haemodialysis patients

21 January 2018

1 reference

The effect of viable Chlamydia pneumoniae on serum cytokines and adhesion molecules in hemodialysis patients

21 January 2018

1 reference

Regional cerebral glucose metabolism in monozygotic twins discordant for Alzheimer's disease

21 January 2018

1 reference

Carotid artery lesions and atherosclerotic risk factors in Japanese hemodialysis patients

21 January 2018

1 reference

Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD).

21 January 2018

1 reference

A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.

21 January 2018

1 reference

Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen

21 January 2018

1 reference

Rational antibacterial vaccine design through genomic technologies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000078146

1 reference

10 August 2017

1 reference